DRNA Dicerna Pharmaceuticals Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Pagan Douglas W.	2. Issuer Name and Ticker or Trading Symbol Dicerna Pharmaceuticals Inc [ DRNA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Financial Officer
(Last)          (First)          (Middle) C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY) 12/15/2021
(Street) LEXINGTON, MA 02421 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2021		M		2050	A	(1)	8377 (2)	D
Common Stock	12/15/2021		F		602 (3)	D	$38.05	7775	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/15/2021		M			2050	(4)	(4)	Common Stock	2050.0	$0	6150	D

Explanation of Responses:
(1)	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
(2)	Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
(3)	Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
(4)	The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Pagan Douglas W. C/O DICERNA PHARMACEUTICALS, INC. 75 HAYDEN AVENUE LEXINGTON, MA 02421			Chief Financial Officer

Signatures
/s/ Douglas Fambrough, attorney-in-fact		12/17/2021
**Signature of Reporting Person		Date